Inhibition of PPARγ during rat pregnancy causes intrauterine growth restriction and attenuation of uterine vasodilation

Frontiers in Physiology

Volumn 4 JUL, Issue , 2013, Pages

  Gokina, Natalia I ^a   Chan, Siu Lung ^a   Chapman, Abbie C ^a   Oppenheimer, Karen ^a   Jetton, Thomas L ^a   Cipolla, Marilyn J ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Ppar ; Preeclampsia; Pregnancy; uterine and mesenteric artery; Vasodilation

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ACETYLCHOLINE; GLUCOSE; LEPTIN; MESSENGER RNA; NITROPRUSSIDE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VASCULOTROPIN RECEPTOR 1;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; FETUS OUTCOME; FETUS WEIGHT; GENE EXPRESSION; INTRAUTERINE GROWTH RETARDATION; MESENTERIC ARTERY; NONHUMAN; RAT; UTERINE ARTERY;

EID: 84884559663     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00184     Document Type: Article

References (55)

1. Alexander, B. T., Bennett, W. A., Khalil, R. A., and Granger, J. P. (2001). Preeclampsia: linking placental ischemia with cardiovascular-renal dysfunction. News Physiol. Sci. 16, 282-286.
2. Asami-Miyagishi, R., Iseki, S., Usui, M., Uchida, K., Kubo, H., and Morita, I. (2004). Expression and function of PPARgamma in rat placental development. Biochem. Biophys. Res. Commun. 315, 497-501. doi: 10.1016/j.bbrc.2004.01.074
3. Bagi, Z., Koller, A., and Kaley, G. (2004). PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 286, H742-H748. doi: 10.1152/ajpheart.00718.2003
4. Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., et al. (1999). PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585-595. doi: 10.1016/S1097-2765(00)80209-9
5. Barak, Y., Sadovsky, Y., and Shalom-Barak, T. (2008). PPAR signaling in placental development and function. PPAR Res. 2008, 142082. doi: 10.1155/2008/142082
6. Barroso, I., Gurnell, M., Crowley, V. E., Agostini, M., Schwabe, J. W., Soos, M. A., et al. (1999). Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880-883.
7. Beyer, A. M., Baumbach, G. L., Halabi, C. M., Modrick, M. L., Lynch, C. M., Gerhold, T. D., et al. (2008). Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 51, 867-871. doi: 10.1161/HYPERTENSIONAHA.107.103648
8. Bishop-Bailey, D. (2000). Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 129, 823-834. doi: 10.1038/sj.bjp.0703149
9. Burton, G. J., Woods, A. W., Jauniaux, E., and Kingdom, J. C. (2009). Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 30, 473-482. doi: 10.1016/j.placenta.2009.02.009
10. Calnek, D. S., Mazzella, L., Roser, S., Roman, J., and Hart, C. M. (2003). Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23, 52-57. doi: 10.1161/01.ATV.0000044461.01844.C9
11. Chan, S. L., Chapman, A. C., Sweet, J. G., Gokina, N. I., and Cipolla, M. J. (2010). Effect of PPARgamma inhibition during pregnancy on posterior cerebral artery function and structure. Front. Physiol., 1:130. doi: 10.3389/fphys.2010.00130
12. Chan, S. L., and Cipolla, M. J. (2011). Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-gamma. FASEB J. 25, 3229-3239. doi: 10.1096/fj.10-175471
13. Desvergne, B., Michalik, L., and Wahli, W. (2006). Transcriptional regulation of metabolism. Physiol. Rev. 86, 465-514. doi: 10.1152/physrev.00025.2005
14. Desvergne, B., and Wahli, W. (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688. doi: 10.1210/er.20.5.649
15. Diaz, M., Bassols, J., Lopez-Bermejo, A., Gomez-Roig, M. D., de Zegher, F., and Ibanez, L. (2012). Placental expression of peroxisome proliferator-activated receptor gamma (PPARgamma): relation to placental and fetal growth. J. Clin. Endocrinol. Metab. 97, E1468-E1472. doi: 10.1210/jc.2012-1064
16. Fournier, T., Tsatsaris, V., Handschuh, K., and Evain-Brion, D. (2007). PPARs and the placenta. Placenta 28, 65-76. doi: 10.1016/j.placenta.2006.04.009
17. Giaginis, C., Spanopoulou, E., and Theocharis, S. (2008). PPAR-gamma signaling pathway in placental development and function: a potential therapeutic target in the treatment of gestational diseases. Expert Opin. Ther. Targets 12, 1049-1063. doi: 10.1517/14728222.12.8.1049
18. Gilbert, J. S., Ryan, M. J., LaMarca, B. B., Sedeek, M., Murphy, S. R., and Granger, J. P. (2008). Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 294, H541-H550. doi: 10.1152/ajpheart.01113.2007
19. Gokina, N. I., and Goecks, T. (2006). Upregulation of endothelial cell Ca2+ signaling contributes to pregnancy-enhanced vasodilation of rat uteroplacental arteries. Am. J. Physiol. Heart Circ. Physiol. 290, H2124-H2135. doi: 10.1152/ajpheart.00813.2005
20. Gokina, N. I., Kuzina, O. Y., and Vance, A. M. (2010). Augmented EDHF signaling in rat uteroplacental vasculature during late pregnancy. Am. J. Physiol. Heart Circ. Physiol. 299, H1642-H1652. doi: 10.1152/ajpheart.00227.2010
21. Halabi, C. M., Beyer, A. M., de Lange, W. J., Keen, H. L., Baumbach, G. L., Faraci, F. M., et al. (2008). Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 7, 215-226. doi: 10.1016/j.cmet.2007.12.008
22. Hewitt, D. P., Mark, P. J., and Waddell, B. J. (2006). Placental expression of peroxisome proliferator-activated receptors in rat pregnancy and the effect of increased glucocorticoid exposure. Biol. Reprod. 74, 23-28. doi: 10.1095/biolreprod.105.045914
23. Isler, C. M., Bennett, W. A., Rinewalt, A. N., Cockrell, K. L., Martin, J. N. Jr., Morrison, J. C., et al. (2003). Evaluation of a rat model of preeclampsia for HELLP syndrome characteristics. J. Soc. Gynecol. Investig. 10, 151-153. doi: 10.1016/S1071-5576(03)00009-1
24. Kallen, C. B., and Lazar, M. A. (1996). Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. U.S.A. 93, 5793-5796. doi: 10.1073/pnas.93.12.5793
25. Kanie, N., Matsumoto, T., Kobayashi, T., and Kamata, K. (2003). Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats. Br. J. Pharmacol. 140, 23-32. doi: 10.1038/sj.bjp.0705414
26. Ketsawatsomkron, P., Lorca, R. A., Keen, H. L., Weatherford, E. T., Liu, X., et al. (2012). PPARgamma regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity. Circ. Res. 111, 1446-1458. doi: 10.1161/CIRCRESAHA.112.271577
27. Ketsawatsomkron, P., Pelham, C. J., Groh, S., Keen, H. L., Faraci, F. M., and Sigmund, C. D. (2010). Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J. Biol. Chem. 285, 9311-9316. doi: 10.1074/jbc. R109.025031
28. Kleinhenz, J. M., Kleinhenz, D. J., You, S., Ritzenthaler, J. D., Hansen, J. M., Archer, D. R., et al. (2009). Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am. J. Physiol. Heart Circ. Physiol. 297, H1647-H1654. doi: 10.1152/ajpheart.00148.2009
29. Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., et al. (1999). PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4, 597-609. doi: 10.1016/S1097-2765(00)80210-5
30. Kusinski, L. C., Stanley, J. L., Dilworth, M. R., Hirt, C. J., Andersson, I. J., Renshall, L. J., et al. (2012). eNOS knockout mouse as a model of fetal growth restriction with an impaired uterine artery function and placental transport phenotype. Am. J. Physiol. Regul. Integr. Comp. Physiol. 303, R86-R93. doi: 10.1152/ajpregu.00600.2011
31. Law, R. E., Goetze, S., Xi, X. P., Jackson, S., Kawano, Y., Demer, L., et al. (2000). Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101, 1311-1318. doi: 10.1161/01.CIR.101.11.1311
32. Leesnitzer, L. M., Parks, D. J., Bledsoe, R. K., Cobb, J. E., Collins, J. L., Consler, T. G., et al. (2002). Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41, 6640-6650. doi: 10.1021/bi0159581
33. Liu, Y., Bubolz, A. H., Shi, Y., Newman, P. J., Newman, D. K., and Gutterman, D. D. (2006). Peroxynitrite reduces the endothelium-derived hyperpolarizing factor component of coronary flow-mediated dilation in PECAM-1-knockout mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R57-R65. doi: 10.1152/ajpregu.00424.2005
34. Marx, N., Duez, H., Fruchart, J. C., and Staels, B. (2004). Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94, 1168-1178. doi: 10.1161/01.RES.0000127122.22685.0A
35. Marx, N., and Walcher, D. (2007). Vascular effects of PPARgamma activators - from bench to bedside. Prog. Lipid Res. 46, 283-296. doi: 10.1016/j.plipres.2007.05.003
36. Mateev, S., Sillau, A. H., Mouser, R., McCullough, R. E., White, M. M., Young, D. A., et al. (2003). Chronic hypoxia opposes pregnancy-induced increase in uterine artery vasodilator response to flow. Am. J. Physiol. Heart Circ. Physiol. 284, H820-H829.
37. Matsumoto, T., Kobayashi, T., and Kamata, K. (2008). Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals. J. Smooth Muscle Res. 44, 41-55. doi: 10.1540/jsmr.44.41
38. McCarthy, F. P., Drewlo, S., English, F. A., Kingdom, J., Johns, E. J., Kenny, L. C., et al. (2011a). Evidence implicating peroxisome proliferator-activated receptor-{gamma} in the pathogenesis of preeclampsia. Hypertension 58, 882-887. doi: 10.1161/HYPERTENSIONAHA.111.179440
39. McCarthy, F. P., Drewlo, S., Kingdom, J., Johns, E. J., Walsh, S. K., and Kenny, L. C. (2011b). Peroxisome proliferator-activated receptor-gamma as a potential therapeutic target in the treatment of preeclampsia. Hypertension 58, 280-286. doi: 10.1161/HYPERTENSIONAHA.111.172627
40. Moll, W. (2003). Structure adaptation and blood flow control in the uterine arterial system after hemochorial placentation. Eur. J. Obstet. Gynecol. Reprod. Biol. 110(Suppl. 1), S19-S27. doi: 10.1016/S0301-2115(03)00169-6
41. Moncada, S., Rees, D. D., Schulz, R., and Palmer, R. M. J. (1991). Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric-oxide synthesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 88, 2166-2170. doi: 10.1073/pnas.88.6.2166
42. Nicolakakis, N., and Hamel, E. (2010). The Nuclear receptor ppargamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Front. Aging Neurosci., 2:21. doi: 10.3389/fnagi.2010.00021
43. Osol, G., and Mandala, M. (2009). Maternal uterine vascular remodeling during pregnancy. Physiology 24, 58-71. doi: 10.1152/physiol.00033.2008
44. Phillips, J. K., Vance, A. M., Raj, R. S., Mandala, M., Linder, E. A., and Gokina, N. I. (2012). Impact of experimental diabetes on the maternal uterine vascular remodeling during rat pregnancy. Reprod. Sci. 19, 322-331. doi: 10.1177/1933719111424435
45. Roberts, J. (1998). Endothelial dysfunction in preeclampsia. Semin. Reprod. Endocrinol. 16, 5-15. doi: 10.1055/s-2007-1016248
46. Roberts, J. M., Pearson, G., Cutler, J., and Lindheimer, M. (2003). Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension 41, 437-445. doi: 10.1161/01.HYP.0000054981.03589.E9
47. Sharma, S., Barton, J., Rafikov, R., Aggarwal, S., Kuo, H. C., Oishi, P. E., et al. (2013). Chronic inhibition of PPAR-gamma signaling induces endothelial dysfunction in the juvenile lamb. Pulm. Pharmacol. Ther. 26, 271-280. doi: 10.1016/j.pupt.2012.12.004
48. Sibai, B., Dekker, G., and Kupferminc, M. (2005). Pre-eclampsia. Lancet 365, 785-799.
49. Sigmund, C. D. (2010). Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. Hypertension 55, 437-444. doi: 10.1161/HYPERTENSIONAHA.109.144170
50. Stanley, J. L., Andersson, I. J., Poudel, R., Rueda-Clausen, C. F., Sibley, C. P., Davidge, S. T., et al. (2012). Sildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model. Hypertension 59, 1021-1028. doi: 10.1161/HYPERTENSIONAHA.111.186270
51. Waite, L. L., Louie, R. E., and Taylor, R. N. (2005). Circulating activators of peroxisome proliferator-activated receptors are reduced in preeclamptic pregnancy. J. Clin. Endocrinol. Metab. 90, 620-626. doi: 10.1210/jc.2004-0849
52. Waite, L. L., Person, E. C., Zhou, Y., Lim, K. H., Scanlan, T. S., and Taylor, R. N. (2000). Placental peroxisome proliferator-activated receptor-gamma is up-regulated by pregnancy serum. J. Clin. Endocrinol. Metab. 85, 3808-3814. doi: 10.1210/jc.85.10.3808
53. Wareing, M., Myers, J. E., O'Hara, M., and Baker, P. N. (2005). Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J. Clin. Endocrinol. Metab. 90, 2550-2555. doi: 10.1210/jc.2004-1831
54. Wieser, F., Waite, L., Depoix, C., and Taylor, R. N. (2008). PPAR action in human placental development and pregnancy and its complications. PPAR Res. 2008, 527048. doi: 10.1155/2008/527048
55. Zimmermann, P., Eirio, V., Koskinen, J., Kujansuu, E., and Ranta, T. (1997). Doppler assessment of the uterine and uteroplacental circulation in the second trimester in pregnancies at high risk for pre-eclampsia and/or intrauterine growth retardation: comparison and correlation between different Doppler parameters. Ultrasound Obstet. Gynecol. 9, 330-338. doi: 10.1046/j.1469-0705.1997.09050330.x